Levamlodipine Shortage: What Providers and Prescribers Need to Know in 2026

Levamlodipine maleate (Conjupri) is a dihydropyridine calcium channel blocker approved by the FDA in December 2019 for the treatment of hypertension in adults and pediatric patients 6 years and older. While the drug is not on the FDA's Drug Shortage Database as of 2026, many prescribers are receiving calls from patients who cannot fill their prescriptions at their local pharmacy. Understanding the root cause of this availability challenge—and knowing how to respond—is essential for maintaining your patients on effective antihypertensive therapy.

What Is Levamlodipine and Why Do Patients Need It?

Levamlodipine is the pharmacologically active (S)-enantiomer of amlodipine. As a racemic mixture, amlodipine contains equal parts (R)- and (S)-amlodipine, but only the (S)-form blocks L-type calcium channels in vascular smooth muscle. By isolating the active isomer, levamlodipine delivers equivalent antihypertensive efficacy at half the dose: 2.5 mg levamlodipine approximates the BP-lowering effect of 5 mg amlodipine.

The primary clinical benefit of levamlodipine over racemic amlodipine is the substantially reduced risk of peripheral edema. Peripheral edema is the most common adverse event associated with amlodipine and is dose-dependent. In a postmarketing surveillance study of 1,859 patients prescribed levamlodipine, fewer than 2% reported side effects. In patients who switched from amlodipine specifically due to edema, the edema resolved in 98.7% of cases at 4 weeks. For patients with occupational or lifestyle constraints related to lower extremity edema, levamlodipine represents a meaningful therapeutic advancement.

The Availability Problem: Why It's Happening

Levamlodipine is not in an FDA-designated national shortage. The availability problem is structural and systemic:

Low routine stocking: Pharmacies stock based on expected demand. With significantly fewer levamlodipine prescriptions than amlodipine being written, most retail pharmacies don't maintain regular inventory.

Insurance formulary position: Many commercial formularies place levamlodipine on Tier 3 or higher, or require prior authorization. Step therapy that mandates amlodipine first further limits the prescribing base.

Limited generic distribution: Generic levamlodipine maleate is available but hasn't yet achieved the broad wholesale distribution of older generic antihypertensives.

Clinical Management: When a Patient Can't Fill Levamlodipine

When a patient reports difficulty filling their levamlodipine prescription, consider the following algorithm:

Assess immediacy. Is the patient out of medication now, or do they have a few days' supply? Intervene urgently if they are at risk of missing doses.

Direct to a pharmacy-finder service. Services like medfinder call local pharmacies to identify real-time availability. This is the most efficient approach before considering an alternative prescription.

Consider bridging with amlodipine temporarily. If the patient was switched off amlodipine due to edema and tolerability is not an immediate concern, a short amlodipine bridge while arranging levamlodipine supply is clinically reasonable. Use dose equivalence: levamlodipine 2.5 mg ≈ amlodipine 5 mg.

Evaluate alternative antihypertensive classes. If the patient cannot tolerate amlodipine and levamlodipine is consistently unavailable, consider ACE inhibitors, ARBs, or thiazide diuretics based on patient comorbidities and clinical guidelines.

Formulary and Prior Authorization Considerations

If your patient has insurance but levamlodipine requires prior authorization, submitting documentation of amlodipine-associated peripheral edema—with clinical notes—typically supports approval. Key data to include in a PA submission:

Documentation that patient was trialed on amlodipine (date started, dose)

Clinical description of peripheral edema (severity, bilateral, impact on function)

Statement that the patient requires a lower-edema alternative within the same drug class

Rationale for levamlodipine over alternative CCBs (if applicable)

Dosing and Prescribing Summary

For quick reference when prescribing levamlodipine (Conjupri):

Adult starting dose: 2.5 mg orally once daily; max 5 mg/day

Elderly/hepatic impairment: Start at 1.25 mg once daily

Pediatric (6-17 years): 1.25-2.5 mg once daily, max 2.5 mg/day

Titration: Wait 7-14 days between dose adjustments; may titrate faster if clinically warranted with close monitoring

Simvastatin interaction: Limit simvastatin dose to 20 mg/day when co-prescribed with levamlodipine

Grapefruit: Advise patients to avoid grapefruit/grapefruit juice due to CYP3A4 inhibition

How medfinder Can Support Your Patients

Recommending medfinder to patients who report difficulty filling levamlodipine is a practical, low-friction way to help. medfinder calls pharmacies in the patient's area to check real-time stock and texts the patient a list of pharmacies that have the medication available. This reduces the back-and-forth with your office and helps patients stay on therapy without a prescription change.

The Bottom Line for Prescribers

Levamlodipine's pharmacy availability challenge is a distribution issue, not a manufacturing crisis. The drug is available—patients just need help finding it. Equipping your patients with access to pharmacy-finding tools and a clear plan for when they can't find it will prevent unnecessary therapy gaps. For a detailed provider guide, see our article on how to help your patients find levamlodipine in stock.